Tim H. Brummendorf

Aachen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.

Journal: Leukemia

Published: January 12, 2022

Treatment of telomeropathies.

Treatment of telomeropathies.

Journal: Best practice & research. Clinical haematology

Published: June 01, 2021

Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN.

Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN.

Journal: Leukemia research

Published: April 02, 2021

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.

Journal: Annals of hematology

Published: January 31, 2020

Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 01, 2018

Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas.

Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas.

Journal: International journal of molecular sciences

Published: January 12, 2018

Angptl4 is upregulated under inflammatory conditions in the bone marrow of mice, expands myeloid progenitors, and accelerates reconstitution of platelets after myelosuppressive therapy.

Angptl4 is upregulated under inflammatory conditions in the bone marrow of mice, expands myeloid progenitors, and accelerates reconstitution of platelets after myelosuppressive therapy.

Journal: Journal of hematology & oncology

Published: December 17, 2014

Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms.

Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms.

Journal: Journal of hematology & oncology

Published: November 13, 2014

Showing 1-8 of 8

Last Updated: 09/26/2026